Month: July 2020

Crédit Agricole Loire Haute-Loire :Communiqué de presse à fin juin 2020

Written by Customer Service on July 20, 2020. Posted in Earnings Releases And Operating Results.

Communiqué de presse à fin juin 2020Crédit Agricole Loire Haute LoireNYSE Euronext Paris – Eurolist compartiment C – ISIN : FR0000045239Caisse Régionale de Crédit Agricole Mutuel Loire Haute-LoireSt Etienne, publié le 20 juillet 2020Le vendredi 17 juillet 2020, le Conseil d’administration de la Caisse Régionale de Crédit Agricole Loire Haute-Loire a arrêté les comptes sociaux et consolidés à fin juin 2020.Malgré l’impact de la crise sanitaire, une activité bien présente comportant un large plan de soutien de l’économie Les encours de collecte sont en progression de +7% sur un an à 14,5 Mds€. Cette croissance est portée par la collecte bilan (+11,3%).En raison d’une réduction de la consommation induite par les mesures de confinement, l’encours des dépôts à vue s’est fortement accru (+27,6%), de même que l’épargne...

Philips delivers Q2 sales of EUR 4.4 billion, with 6% comparable sales decrease; income from continuing operations of EUR 213 million, Adjusted EBITA margin of 9.5% and operating cash flow of EUR 558 million

Written by Customer Service on July 20, 2020. Posted in Earnings Releases And Operating Results.

July 20, 2020Second-quarter highlights• Sales amounted to EUR 4.4 billion, with a 6% comparable sales decrease• Comparable order intake increased 27%• Income from continuing operations was EUR 213 million, compared to EUR 260 million in Q2 2019• Adjusted EBITA margin was 9.5% of sales, compared to 11.8% of sales in Q2 2019• Income from operations amounted to EUR 229 million, compared to EUR 350 million in Q2 2019• EPS from continuing operations (diluted) amounted to EUR 0.23; Adjusted EPS amounted to EUR 0.35, compared to EUR 0.42 in Q2 2019• Operating cash flow improved to EUR 558 million, compared to EUR 390 million in Q2 2019• Free cash flow increased to EUR 311 million, compared to EUR 174 million in Q2 2019In the quarter, Philips’ sales declined 6% on a comparable basis...

Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

Written by Customer Service on July 20, 2020. Posted in Public Companies.

Thirty million doses expected to be delivered in 2020 and 2021, subject to regulatory approval or authorizationPfizer and BioNTech remain on track to begin an anticipated Phase 2b/3 safety and efficacy trial later this month, seek regulatory review as early as October 2020 and manufacture globally up to 100 million doses by the end of 2020 and more than 1.3 billion doses by the end of 2021Agreement is part of Pfizer’s and BioNTech’s global commitment to help address the pandemicNEW YORK and MAINZ, Germany, July 20, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details...

Pfizer und BioNTech geben Vereinbarung mit dem Vereinigten Königreich über 30 Millionen Dosen eines mRNA-basierten Impfstoffkandidaten gegen SARS-CoV-2 bekannt

Written by Customer Service on July 20, 2020. Posted in Public Companies.

30 Millionen Dosen werden voraussichtlich 2020 und 2021 geliefert, vorbehaltlich der behördlichen Genehmigung oder ZulassungPfizer und BioNTech sind im Zeitplan, noch diesen Monat die erwartete Phase-2b/3-Sicherheits- und Wirksamkeitsstudie zu beginnen, bereits im Oktober das Zulassungsverfahren zu beantragen, sowie bis zu 100 Millionen Impfstoffdosen bis Ende 2020 sowie über 1,3 Milliarden Impfstoffdosen bis Ende 2021 herzustellenDie Vereinbarung ist Teil des globalen Engagements von Pfizer und BioNTech bei der Bekämpfung der PandemieNEW YORK und MAINZ, Deutschland, July 20, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute den Abschluss einer Vereinbarung mit dem Vereinigten Königreich über die Lieferung von 30 Millionen Dosen ihres sich in der klinischen Entwicklung befindlichen mRNA-basierten...

Notice of ARYZTA Extraordinary General Meeting

Written by Customer Service on July 20, 2020. Posted in Public Companies.

Schlieren/Switzerland, 20 July 2020 AttachmentRelease

Santhera to Join SIX Swiss Exchange Life Science Industry Indices

Written by Customer Service on July 20, 2020. Posted in Public Companies.

Pratteln, Switzerland, July 20, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces its inclusion in the SXI Life Sciences® (SIX/Bloomberg: SLIFEX) and SXI Bio+Medtech® (SIX/Bloomberg: SBIOMX) indices of the SIX Swiss Exchange.Following the SIX Swiss Exchange’s ordinary index review, Santhera has been informed that it meets the criteria for inclusion in two healthcare indices: SXI Life Sciences®, which includes pharmaceutical, biotechnology and medical technology companies, and its more narrowly defined sub-index SXI Bio+Medtech®, focused on biotech and medtech companies. Santhera’s inclusion in both indices will be effective on September 21, 2020.“We are pleased to be included in these important life science industry indices, which will contribute to raising Santhera’s profile and heighten its visibility in the international investor...

Santhera wird in die Life-Science-Branchenindizes der SIX Swiss Exchange aufgenommen

Written by Customer Service on July 20, 2020. Posted in Public Companies.

Pratteln, Schweiz, 20. Juli 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt die Aufnahme des Unternehmens in die Indizes SXI Life Sciences® (SIX/Bloomberg: SLIFEX) und SXI Bio+Medtech® (SIX/Bloomberg: SBIOMX) der SIX Swiss Exchange bekannt.Im Anschluss an die ordentliche Indexüberprüfung durch die SIX Swiss Exchange wurde Santhera darüber informiert, dass das Unternehmen die Kriterien für die Aufnahme in zwei Healthcare-Indizes erfüllt: den SXI Life Sciences® Index, der Pharma-, Biotechnologie- und Medizinaltechnologie-Unternehmen umfasst, und sein enger gefasster Subindex SXI Bio+Medtech®, der auf Biotech- und Medtech-Unternehmen fokussiert. Die Aufnahme von Santhera in beide Indizes erfolgt per 21. September 2020.„Wir freuen uns über die Aufnahme in diese wichtigen Indizes der Life-Science-Industrie, was dazu beitragen wird,...

Competition Authority grants permission to LHV Pank to acquire the unit of Danske Bank involved with Estonian corporate and public sector credits

Written by Customer Service on July 20, 2020. Posted in Public Companies.

On 17 July 2020, the Estonian Competition Authority granted AS LHV Pank a concentration permit, fulfilling the prerequisite for the transaction between AS LHV Pank and Danske Bank A/S. According to the agreement LHV Pank will acquire Danske Bank’s Estonian corporate and public sector credit portfolio (disclosed in 8 June Market Announcement). The transaction will be finalised in October of the current year, when the final scope and price of the transaction will also be determined. Priit RumLHV Communication ManagerTelephone: 502 0786E-mail: priit.rum@lhv.ee

Konkurentsiamet andis LHV Pangale loa Danske Banki Eesti ettevõtjate ja avaliku sektori krediidiga seotud käitise ostuks

Written by Customer Service on July 20, 2020. Posted in Public Companies.

Konkurentsiamet andis 17. juulil 2020 AS-le LHV Pank koondumisloa, mis oli eelduseks AS-i LHV Pank ja Danske Bank A/S-i vahelise tehingu lõpuleviimisele. Tehingu kohaselt omandab LHV Pank Danske Banki Eesti ettevõtjate ja avaliku sektori laenuportfelli (avalikustatud 8. juuni börsiteatega). Tehing viiakse lõpule käesoleva aasta oktoobris, siis kujunevad ka tehingu lõplik maht ja hind.Priit RumLHV kommunikatsioonijuhtTelefon: 502 0786E-post: priit.rum@lhv.ee

Van Leeuwenhoeck Issues Updated Addex Equity Research Report

Written by Customer Service on July 20, 2020. Posted in Public Companies.

Geneva, Switzerland, July 20, 2020 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that the independent life science equity research company, Van Leeuwenhoeck, has issued an equity research report highlighting the Addex investment opportunity and a valuation of CHF13-14 per share. Analyses in the report notes a significant undervaluation of Addex, which is trading currently at CHF1.40 per share, as well as key near term value drivers including the start of a pivotal registration study of dipraglurant for levodopa-induced dyskinesia associated with Parkinson’s disease and the recently announced decision of Addex partner Janssen Pharmaceuticals Inc., to advance ADX71149 into a Phase 2a proof of concept study in epilepsy.“We believe Addex is fundamentally...

Month: July 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals